Assessing Oxygenation Response to Eribulin in a Patient with Recurrent Breast Cancer after Resistance to Endocrine TherapyShigeto Ueda1, Toshiaki Saeki1*, Tomohiko Yamane2, Ichiei Kuji2
- *Corresponding Author:
- Toshiaki Saeki
Department of Breast Oncology
International Medical Center, Saitama Medical University, 1371-1 Yamane
Hidaka, 350-1298, Japan
E-mail: [email protected]
Received Date: January 23, 2017; Accepted Date: January 25, 2017; Published Date: January 30, 2017
Citation: Ueda S, Saeki T, Yamane T, Kuji I (2017) Assessing Oxygenation Response to Eribulin in a Patient with Recurrent Breast Cancer after Resistance to Endocrine Therapy. OMICS J Radiol 6:250. doi: 10.4172/2167-7964.1000250
Copyright: © 2017 Ueda S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
We present our initial experience with a novel method of functional hypoxia imaging. 18F-fluoromisonidazole-positron emission tomography/computed tomography and diffuse optical spectroscopic imaging were used to noninvasively evaluate the biological effects induced by eribulin monotherapy in a patient treated for recurrent breast cancer with acquired resistance to endocrine therapy. Eribulin monotherapy clearly induced reoxygenation, indicated by the markedly reduced 18F-fluoromisonidazole uptake and enhanced oxygen saturation levels in the lesion. These observations suggest that the reversal of hypoxia can be captured utilizing 18F-fluoromisonidazole positron emission tomography/computed tomography and diffuse optical spectroscopic imaging.